<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03985046</url>
  </required_header>
  <id_info>
    <org_study_id>ESO-Shanghai14</org_study_id>
    <nct_id>NCT03985046</nct_id>
  </id_info>
  <brief_title>Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC</brief_title>
  <official_title>A Pilot Study of Sintilimab Plus Chemotherapy Followed by Definitive Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe and evaluate the efficacy and safety of A sintilimab&#xD;
      plus chemotherapy followed by definitive concurrent chemoradiotherapy in locally advanced&#xD;
      esophageal squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Control Rate</measure>
    <time_frame>up to 42 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>up to 42 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 42 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sintilimab plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab plus Chemotherapy</intervention_name>
    <description>Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=6. Once every 3 weeks.</description>
    <arm_group_label>Sintilimab plus chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent&#xD;
&#xD;
          2. Aged 18-75 years&#xD;
&#xD;
          3. Histologically confirmed esophageal squamous cell carcinoma&#xD;
&#xD;
          4. Clinical stages T3-4N0M0 or TxN1M0 or TxNxM1a or TxNxM1b (Only for cervical lymph&#xD;
             nodes or celiac lymph nodes metastasis) based on the 6th UICC-TNM classification&#xD;
&#xD;
        7. Eastern Cooperative Oncology Group(ECOG) performance status: 0-1 8. Life expectancy ≥3&#xD;
        months 9. Adequate organ functions Absolute neutrophil counts (ANC) ≥1.5×109⁄L; Hemoglobin&#xD;
        (Hb) ≥9g⁄dl; Platelet (Plt) ≥100×109⁄L; Total bilirubin ≤1.5 upper limit of normal (ULN);&#xD;
        Aspartate transaminase (AST) ≤2.5 ULN; Alanine aminotransferase (ALT) ≤2.5 ULN; Creatinine&#xD;
        ≤1.5 ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Esophageal perforation or hematemesis&#xD;
&#xD;
          2. Any active autoimmune disease or a history of autoimmune disease (such as the&#xD;
             following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis,&#xD;
             enteritis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism and&#xD;
             hypothyroidism (effective hormone replacement therapy excepted)) and immunosuppressive&#xD;
             agents or systemic hormonal therapy indicated within 28 days (for adverse events of&#xD;
             chemoradiotherapy excepted).&#xD;
&#xD;
          3. Previously received or receiving other PD-1 antibody therapy or other immunotherapy&#xD;
             against PD-1/PD-L1.&#xD;
&#xD;
          4. Allergic to macromolecular protein preparations, or to any of the ingredients in&#xD;
             sintilimab for injection.&#xD;
&#xD;
          5. Uncontrolled heart diseases or clinical symptoms, such as: (1) New York Heart&#xD;
             Association(NYHA) class II or higher heart failure; (2) unstable angina; (3)&#xD;
             myocardial infarction within 1 year; (4)clinically significant arrhythmia requiring&#xD;
             clinical intervention.&#xD;
&#xD;
          6. Congenital or acquired immunodeficiency (such as HIV infection); active hepatitis B&#xD;
             (HBV-DNA≥104 copy number/ml) or hepatitis C (positive hepatitis C antibody, and&#xD;
             HCV-RNA is higher than the detection limit of the analytical method); active&#xD;
             tuberculosis.&#xD;
&#xD;
          7. Active infection or unexplained fever &gt;38.5 °C within 2 weeks before randomization&#xD;
             (fever due to tumor excepted, according to investigator).&#xD;
&#xD;
          8. Patients with fertility reluctant to take contraceptive measures during the trial, or&#xD;
             female patients pregnant or breastfeeding.&#xD;
&#xD;
          9. According to the investigator, other factors that may cause termination of the study.&#xD;
             ie, other serious diseases (including mental illness) require combined treatment,&#xD;
             family or social factors, which may affect the safety or the collection of trial data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fudan Universtiy Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Kuai Le Zhao, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

